
FDA Oncology Biologics Guidance: Nonclinical Safety Studies
This analysis explains the May 2026 FDA draft guidance on nonclinical safety studies for oncology biologics, single-species toxicology, and WoE approaches.
IntuitionLabs is now a member of the Claude Partner Network – AI training and upskilling with Claude for pharma and biotech. Book a call.

This analysis explains the May 2026 FDA draft guidance on nonclinical safety studies for oncology biologics, single-species toxicology, and WoE approaches.
© 2026 IntuitionLabs. All rights reserved.